Ontology highlight
ABSTRACT: Background
Cardiac glycosides (CGs), such as digitoxin, are traditionally used for treatment of congestive heart failure; recently they also gained attention for their anticancer properties. Previous studies showed that digitoxin and a synthetic L-sugar monosaccharide analog treatment decreases cancer cell proliferation, increases apoptosis, and pro-adhesion abilities; however, no reports are available on their potential to alter lung cancer cell cytoskeleton structure and reduce migratory ability. Herein, we investigated the anticancer effects of digitoxin and its analog, digitoxigenin-α-L-rhamnoside (D6MA), to establish whether cytoskeleton reorganization and reduced motility are drug-induced cellular outcomes.Methods
We treated non-small cell lung carcinoma cells (NSCLCs
SUBMITTER: Eldawud R
PROVIDER: S-EPMC7484221 | biostudies-literature | 2020 Nov
REPOSITORIES: biostudies-literature